In addition, hyperinsulinemia also increases IGF-I bioavailability through the downregulation of insulin-like growth factor binding protein-1 (IGFBP-1) and IGFBP-2, which both may inhibit IGF-I actions [148,149] (Figure 5). The gene discussed is IGFBP1; the disease is Hyperinsulinemia.